The multidisciplinary approach to colorectal cancer has been well accepted,recently. Meanwhile,individualized drug therapy has been developed by the guidance of molecular subtyping. Colorectal cancer is a heterogeneous disease that develops as a consequence of both genetic and epigenetic events. In the new era of big data and precision medicine,the molecular subtype of colorectal cancer is becoming more and more important,including differentiation of molecular biomarkers and locations of cancer. The future direction of colorectal cancer treatment should focus on dissecting tumor heterogeneity,distinguishing individual biological behavior,and practicing precision medicine.